norLeu3-A(1-7)

05/01/2005 - "With administration of NorLeu3-A(1-7), significantly fewer incisions had observable scars starting on day 14 and throughout the study. "
05/01/2005 - "Effect of NorLeu3-A(1-7) on scar formation over time after full-thickness incision injury in the rat."
03/01/2003 - "Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7)."
03/01/2003 - "Administration of NorLeu3-A(1-7) reduced fibrosis and scarring in the healing wounds. "
05/01/2005 - "Previous studies have shown that the angiotensin peptide NorLeu3-A(1-7) accelerates dermal healing and reduces scar formation. "

07/01/2012 - "NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial."
03/01/2003 - "NorLeu3-A(1-7) was superior to the naturally occurring angiotensin peptide angiotensin(1-7) and to Regranex (Ortho McNeil, Somerville, N.J.) (a formulation of recombinant platelet-derived growth factor used clinically for the treatment of diabetic ulcers) in accelerating tissue repair. "

07/01/2012 - "NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial."

03/01/2003 - "Full healing was observed for 60 percent of the diabetic mice treated topically with NorLeu3-A(1-7) by day 18 after injury, at which time full healing of wounds on placebo-treated or Regranex-treated diabetic mice was not observed. "
03/01/2003 - "By day 9 (normal rats) and day 11 (diabetic mice), the differences in the rates of closure of full-thickness excision wounds between NorLeu3-A(1-7) and Regranex were statistically significant (n = 5 per group). "
03/01/2003 - "Administration of NorLeu3-A(1-7) reduced fibrosis and scarring in the healing wounds. "

03/01/2003 - "Administration of NorLeu3-A(1-7) reduced fibrosis and scarring in the healing wounds. "